Is Abbott building the next integrated platform for complex heart rhythm treatment?
Abbott has PFA momentum, but rhythm care is becoming a platform battle. Can clinical data turn into durable adoption?
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Can BrioHealth’s Brio4Kids trial close the pediatric LVAD gap in advanced heart failure?
Pediatric heart failure lacks durable LVAD choices. BrioHealth’s Brio4Kids trial now tests whether BrioVAD can narrow that gap.
Medical Devices & Diagnostics
Is EASYMADE TI the breakthrough CGBIO needs in patient-specific craniofacial reconstruction?
Customized implants are moving from niche to surgical workflow. CGBIO’s U.S. clearance tests whether speed can become a medtech edge.
Medical Devices & Diagnostics
Vapotherm FDA clearance expands HVT 2.0 use from neonatal to adult respiratory care
Find out how Vapotherm’s FDA-cleared All Patient Circuit could simplify high velocity therapy from neonatal to adult care.
Medical Devices & Diagnostics
Why Sonorous Neurovascular’s BosCATH FDA clearance could matter more than it first appears
Find out how Sonorous Neurovascular’s BosCATH FDA clearance strengthens its neurovascular access strategy today!
Medical Devices & Diagnostics
Can Utepreva’s new device solve the biggest problem in endometrial cancer diagnosis?
Utepreva’s FDA-cleared endometrial sampler promises earlier cancer detection. Find out how this device could reshape diagnostics today.
Medical Devices & Diagnostics
Could Reflow Medical’s new Cora microcatheters fix a hidden pain point in complex PCI?
Find out how Reflow Medical’s Cora Flex and Cora Force launch could reshape complex coronary intervention workflows.
Medical Devices & Diagnostics
Can Anaxiom’s AVOS device open a new minimally invasive route in obesity treatment?
Find out how Anaxiom’s AVOS obesity device could reshape minimally invasive weight-loss treatment after early human results.
Medical Devices & Diagnostics
Could XVIVO’s HOPE data change how long donor hearts can survive outside the body?
See how XVIVO’s PRESERVE Trial data could reshape donor heart preservation, FDA review, and transplant access.
Medical Devices & Diagnostics
BNB Plus completes record LineaDNA order as strategic review puts LineaRx in sharper focus
BNB Plus completed a record $1.2 million LineaDNA order for LineaRx. Read what it means for scale, margins, strategy, and BNBX stock sentiment.